Abstract | BACKGROUND/AIMS: METHODOLOGY: One hundred sixty-three patients on which ESD was performed were randomly allocated to either two groups: one treated with lansoprazole (30mg/day) and the other with lansoprazole (30mg/day) plus polaprezinc (150mg/day) for the treatment of ESD-induced ulcer. The condition of the ESD-induced ulcer was blindly assessed two months after ESD by two physicians. RESULTS:
Lansoprazole plus polaprezinc group showed significantly better ulcer healing (p < 0.0001) and protrusion of the ulcer base was recognized in only 1.3% (1/77), an incidence significantly lower than that in lansoprazole group (20.7%, 16/77, p = 0.0001). Polaprezinc was the only significant factor (p = 0.0001) differentiating patients who had ulcer base protrusion (n = 17) from those who did not (n = 137). CONCLUSIONS:
|
Authors | Tomoki Inaba, Shigenao Ishikawa, Tatsuya Toyokawa, Hisashi Ishikawa, Koji Miyahara, Masaki Wato, Kozo Kawai, Hiroyuki Okada, Kazuhide Yamamoto |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
2010 May-Jun
Vol. 57
Issue 99-100
Pg. 678-84
ISSN: 0172-6390 [Print] Greece |
PMID | 20698249
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Organometallic Compounds
- Proton Pump Inhibitors
- Zinc Compounds
- Lansoprazole
- polaprezinc
- Carnosine
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
(administration & dosage, therapeutic use)
- Aged
- Carnosine
(administration & dosage, analogs & derivatives, therapeutic use)
- Cytoprotection
- Drug Therapy, Combination
- Female
- Gastric Mucosa
(surgery)
- Humans
- Lansoprazole
- Male
- Middle Aged
- Organometallic Compounds
(administration & dosage, therapeutic use)
- Postoperative Complications
(drug therapy)
- Proton Pump Inhibitors
(therapeutic use)
- Stomach Neoplasms
(surgery)
- Stomach Ulcer
(drug therapy, etiology, pathology)
- Wound Healing
- Zinc Compounds
(administration & dosage, therapeutic use)
|